Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

STOCKHOLM, SWEDEN ( - Infection with human papillomavirus (HPV) is a known risk factor for penile cancer (PC) development.

The reported proportion of PC associated with high-risk HPV ranges from 30% to 100%. Given the rising incidence of HPV-associated head and neck squamous cell cancer, Dr. Djajadiningrat and colleagues sought to assess the prevalence of high-risk HPV in a contemporary cohort of patients with PC. PC specimens from 213 patients, treated between 2001 and 2009, were tested for high-risk HPV DNA using PCR. Positive samples were then typed using a reverse line blot assay. Survival rates were calculated and compared based on the presence of high-risk PC.

eauFifty-three men (25%) had high-risk HPV DNA detected in their specimen, with a predominance of subtype 16 (79%). At a median follow-up of 59 months (range 40-68 months), 5-year cancer-specific survival was 82% and 96% in patients with high-risk HPV-negative and positive disease, respectively. As has been previously described, HPV infection is present in a small subset of PC patients, and the prevalence of HPV-associated PC has not increased over the past decade. Further, infection with high-risk HPV (as evidenced by the presence of high-risk HPV DNA) appears to confer a survival advantage for patients with PC.

Presented by R.S. Djajadiningrat at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden

The Netherlands Cancer Institute, Department. of Urology, Amsterdam, Netherlands

Written by Jeffrey J. Tomaszewski, MD, medical writer for


Clinical Trials
Searchable data base of currently enrolling clinical trials
Upcoming urology industry events
February 26-27, 2018 / The Royal Marsden Hospital
MediSens – The European Medical Imaging Conference
February 27-March 3, 2018 /
SUFU 2018 Winter Meeting
March 1-3, 2018 / Omni Amelia Island Plantation Resort, Fernandina Beach, FL
75th Annual Meeting Mid-Atlantic Section of the American Urological Association
March 1-3, 2018 / Marriott St. Louis Airport, St. Louis, Missouri
2018 Bladder Cancer Academy
March 3, 2018 / DoubleTree by Hilton Hotel Dallas - Campbell Centre
Advances in Cancer Immunotherapy™ - Dallas, TX
Print publications focusing on urological cancer treatments through original commentary & articles

Everyday Urology™ - Oncology Insights

From the Editor

Prostate Cancer and Prostatic Diseases

From the Editor